Literature DB >> 30067206

[NK cells: a major role in the antitumoral immunomodulation in CML].

Antoine Toubert1, Ali Turhan2, Agnès Guerci-Bresler3, Nicolas Dulphy1, Delphine Réa4.   

Abstract

Convincing clinical and experimental evidence is converging on the essential role of NK (Natural Killer) cells in the recognition and eradication of tumors. Recent studies emphasized the role of NK cells in the immune control of chronic myeloid leukemia (CML), a malignancy arising from hematopoietic stem cells, and the treatment of which has been revolutionized by the use of tyrosine kinase inhibitors (TKI). Three major findings are emerging: 1) the impairment of the numbers and function of NK cells at diagnosis, 2) the restoration of the NK cell function and numbers during remissions induced with TKI therapies and 3) the potential role of the more mature NK CD56dim cell population in maintaining relapse-free survival after stopping TKI therapy. Immunological control of CML by NK cells which has been suspected for several decades is thus a new field of investigation for future therapies.
© 2018 médecine/sciences – Inserm.

Entities:  

Mesh:

Year:  2018        PMID: 30067206     DOI: 10.1051/medsci/20183406013

Source DB:  PubMed          Journal:  Med Sci (Paris)        ISSN: 0767-0974            Impact factor:   0.818


  1 in total

1.  Increased Expression of TIGIT/CD57 in Peripheral Blood/Bone Marrow NK Cells in Patients with Chronic Myeloid Leukemia.

Authors:  Danlin Yao; Ling Xu; Lian Liu; Xiangbo Zeng; Juan Zhong; Jing Lai; Runhui Zheng; Zhenyi Jin; Shaohua Chen; Xianfeng Zha; Xin Huang; Yuhong Lu
Journal:  Biomed Res Int       Date:  2020-10-13       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.